My watch list  


Systematic (IUPAC) name
1-Methyl-d-lysergic acid-(1-hydroxybut-2-yl)amide
CAS number 361-37-5
ATC code N02CA04
PubChem 9681
DrugBank APRD00463
Chemical data
Formula C21H27N3O2 
Mol. mass 353.458 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes  ?

Methysergide (UML-491) is a prescription drug used for prophylaxis of migraine headaches and is sold under the brand names Sansert and Deseril in 2mg dosages. Methysergide was approved by the FDA in 1962. Its molecular structure is closely related to that of LSD. It is a 5-HT (serotonin) antagonist. It is a receptor antagonist for the 5-HT receptor 2C[1].

Methysergide is one of the most effective medications for the prevention of migraine, but not for the treatment of an acute attack. It has a known side effect, retroperitoneal fibrosis[2], which is severe, although uncommon. Novartis withdrew it from the U.S. market after taking over Sandoz, but currently lists it as a product.

Like LSD, methysergide also produces psychedelic and hallucinogenic effects above a dosage of about 4mg.[3] Full effects are felt with dosages of 8-20mg.[citation needed]

See also



  1. ^ Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4.  Page 187
  2. ^ (2002)
  3. ^ L. Bender (1970): "Children's Reactions to Psychotomimetic Drugs", Psychotomimetic Drugs, pp. 265-273]
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Methysergide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE